• During the live type-B meeting, PaxMedica discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One HAT, also called African Sleeping Sickness
• The FDA is allowing PaxMedica to use previous data from early tests of suramin to begin developing the drug for use in current cases of HAT
• PaxMedica received constructive feedback, which will aid in completing the remaining work necessary to file a New Drug Application (“NDA”), expected in the second half of 2024
• The global ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced the completion of a type-B meeting with the Food and Drug Administration. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated (https://ibn.fm/m7n6V).

Suramin sodium was created as a treatment for people who contracted a deadly form of Human African Trypanosomiasis (“HAT”), a form of sleeping sickness. The FDA is allowing PaxMedica to use previous data from early tests of suramin to begin developing the drug for use in current cases of HAT.

The intention for PaxMedica is to sell the drug’s approval PRV (Priority Review Voucher) for suramin for HAT to big pharma companies and raise the necessary funding needed to explore suramin for use in ASD treatments. The first step in approving suramin for HAT was the type-B meeting with the FDA. The company anticipates the next steps will drive the future of their important research and development efforts.

PaxMedica received constructive feedback, which will aid in completing the remaining work necessary to file a New Drug Application (“NDA”), expected in the second half of 2024. Most of the work to achieve this important milestone will focus on completing the production of commercial lots of PAX-101 under CMC regulatory guidelines, which are underway now and scheduled to conclude in the first half of 2024.

“This is an important turning point for our young company, and we are very pleased with the guidance the FDA provided us in this meeting,” said Howard Weisman, CEO and Chairman of PaxMedica. “We look forward to urgently completing the necessary steps in the coming months to clear the path to submit our first NDA for PAX-101.”

According to Fortune Business Insights, the global ASD therapeutics market was valued at $1.93 billion in 2022. This market is projected to grow at a CAGR of 7.9%, resulting in a value of $3.42 billion by 2030. According to a 2020 CDC report, it is estimated that 1 out of 54 children have been diagnosed with ASD in the United States – the growing prevalence of the disease coupled awareness about the condition and available treatments are key factors expected to with the rising drive the ASD therapeutics market growth (https://ibn.fm/1Ylzn).

The company’s lead programs are focused on ASD (Autism Spectrum Disorder). Currently there is no approved pharmacologic treatment that effectively targets ASD’s cause as well as symptoms. The only treatments available on the market are designed to address symptoms of the condition rather than targeting the pathophysiology itself. PaxMedica is on a promising path to address these critical unmet medical needs and bring hope to millions.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• Strategic metals supply chain innovator Ucore Rare Metals Inc. has developed a proprietary technology it expects to improve rare earth element (“REE”) processing, and is preparing for commercial use of its solution
• The REE supply chain has become a matter of concern to Western governments as well as private industry because of the tremendous market dominance enjoyed by the People’s Republic of China and fears China will exploit that dominance with increasing export restrictions
• Ucore is currently demonstrating the ability of its RapidSX(TM) REE processing solution to match and / or exceed the capacity of industry-standard CSX processing technology while improving on its costs and ease of use
• The company has acquired property in Louisiana it intends to develop during the next year into a commercial-use REE processing center, using American REE feedstock

China’s recently announced controls on reporting exports of rare earth metallic elements (“REEs”) used strategically for permanent magnets in computerized products is the latest salvo in the ongoing trade war between the large Asian nation and the United States, prompting further emphasis on the need for Western independence from China-based supply chains.

Strategic metals enterprise Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is a company operating in Canada and the United States to improve the production of REEs in the Americas and reduce dependence on supply chains that flow through China.

Since China began taking advantage of inexpensive labor to affect the price of REE supply decades ago, U.S. production of REEs has dwindled to the point that only one REE mine is operating in the United States, and it sends its ore to China for processing that separates the desired elements from their host ore.

China controls 60 percent of mined REE resources in the global market, 87 percent of the mid-stream processing and 90 percent-plus of the downstream product creation, according to Ucore CEO Pat Ryan (https://ibn.fm/1zGaG).

The controls announced earlier this month require Chinese REE exporters to report their shipment orders to the government beginning Dec. 1 and continuing through October 2025. Although no restrictions accompany the reporting requirement, the policy is regarded as a reaction to U.S. restrictions on exports of high-end semiconductors and a potential precursor to limits on international REE trade (https://ibn.fm/W71I3).

Such a possibility was further underscored by China’s decision in late November to require exporters of its high-grade graphite — another mineral strategically critical to the manufacture of computerized products and clean energy resources — to apply for government approval, allowing authorities to pick and choose which companies will be able to import Chinese graphite if it chooses, according to a Washington Post report (https://ibn.fm/oyQIO).

Ucore’s proprietary RapidSX(TM) REE processing solution is the key to its strategy to promote Western supply chain independence from Chinese controls. The company has been using RapidSX(TM) to process REEs in head-to-head testing at a Canadian facility against the standard CSX separation technology used globally throughout the industry, and Ucore is preparing to launch construction of a facility in the United States that will use RapidSX(TM) for commercial REE processing.

The U.S. and Canada national governments have both announced they will provide millions of dollars in funding to help Ucore achieve its goals, given REEs’ strategic importance to national clean energy policies and the products used in national defense infrastructure.

The reporting requirements for graphite exports are “a warning shot for sure,” Emily Benson, a senior fellow at the Center for Strategic and International Studies focusing on trade and technology, told the Washington Post for its report. “Will they really bite? Probably not, but it’s a sign that the more tools you use to combat China economically, the greater the risk of retaliation.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Mountain Top Properties is seeking to capitalize on the Hamptons real estate market through its maiden investment fund, Mountain Top Capital Fund I LLC
• In conjunction with renowned contractor, On Site Builder Construction, the fund will seek to acquire, build, renovate, and resell homes in the exclusive Long Island enclave
• Mountain Top Capital Fund have announced plans to raise up to $75 million to fund its commercial endeavours, with a significant amount of debt capital already secured to fund operations
• Brokers say that despite several slowing factors, the luxury market are still bidding and buying the Long Island beach homes

Memorial Day weekend marks the traditional opening of the Hamptons summer season, with thousands of visitors making the journey to one of the world’s most famous summertime destinations in an array of vehicles, boats and jets. Those arriving at the wealthy cluster of seaside enclaves on the eastern tip of Long Island are likely to encounter some of the grandest and most luxurious homes on the eastern seaboard, properties that have historically been the playground of America’s elite – and commanded prices commensurate to their relative grandeur.

Mountain Top Properties (OTC: MTPP), a diversified real estate holding company focused around acquiring, marketing and operating assets through its wholly owned affiliates has now sought to revolutionize hitherto exclusive Hamptons real estate market, through subsidiary, Mountain Top Realty Inc. The managing partner of Mountain Top Properties’ maiden real estate fund focused on residential redevelopment within the Hamptons’ exclusive beachfront communities, Mountain Top Realty Inc. has partnered with On Site Builder Construction Co. Inc., as their design partner in their ambitious endeavour (https://ibn.fm/MTPP).

Helmed by Joseph Kelley, On Site Builder Construction have gained a well-earnt reputation for building some of the Hamptons’ highest quality homes over the past four decades spanning a broad plethora of architectural styles – ranging from classic homes through to ultra-modern, glass-encased seaside mansions. Having built over 60 homes in the seaside retreat, Kelley and On-Site Builder Construction have the distinction of being the original builder for the Hampton’s most expensive properties in both, 2019 and 2022 – the latter at a remarkable $118,500,000 price point. Now and going forward, Mountain Top and On Site Builder Construction’s partnership will seek to leverage upon Joseph Kelley and team’s reputation and technical know-how within the Hamptons real estate market to make the shift from one-off, customized homes through to the provision of finished, turnkey properties to prospective buyers.

Through its Mountain Top Capital Fund I, Mountain Top Realty has sought to raise $75 million to acquire, renovate and remarket homes in the Hamptons; thus far, the fund has already received debt capital commitments amounting to 70 percent of their anticipated real estate acquisition costs, as well as a further 100 percent of the planned construction costs – and will look to deploy $10 million in the future to leverage strategic waterfront opportunities within the exclusive enclave.

As coveted as the Hamptons real estate may seem, the island’s housing prices hit an all-time high due to the stinginess of the market. The average price of a home in the Hamptons hit a record $3 million in the first quarter, due to the lack of homes available for sale, eventually leading to a drop in total deals, with sales volume down 57% in the first quarter (https://ibn.fm/UyIqg). Though not all is totally doubtful, as the high ends of the Hamptons market seem virtually “unfazed”. This luxury market – consisting of the top 10% of sales – broke multiple records during the first quarter, with the average luxury price surging 33% to $16.1 million, according to Jonathan Miller, CEO of Miller Samuel.

Brokers also added that many of the of the current listings are not priced right. With there being more interest from buyers than there are homes available in the Long Island community, Mountain Top Properties aims to turn this shortage around as sales are hoped to pick back up as more homes become available.

For more information, visit the company’s website at www.Mountain-Top-Properties.com.

NOTE TO INVESTORS: The latest news and updates relating to MTPP are available in the company’s newsroom at https://ibn.fm/MTPP

Professionals working in the pharma, medical device, and biotechnology companies, are invited to attend the DGE event, Incorporate Patient Voice Across the Commercial Product Lifecycle being held in Philadelphia on January 25-26, 2024. A live-streaming option for the event is also available.

The event is organized by Dynamic Global Events (“DGE”), a leading life science B2B event organizing company. DGE provides dynamic informational and networking support to the pharmaceutical, biotechnology, healthcare, and medical devices verticals.

This program will educate professionals working in patient engagement and experience and commercial teams on how to access patient insights and incorporate into product launches and patient support services.

Topics of discussion include:

• Learn the current innovations in patient engagement
• Understand and validate patient feedback
• Get case studies for turning patient insights into actionable data
• Put patients at the center of market access, evidence and value based strategy
• Design better initiatives for disease awareness and patient education

Industry experts and top executives attending the event will discuss the key takeaways, that include offering end-to-end support for patients in several areas, namely disease awareness, patient education, and marketing. With better patient insights being incorporated into product lifecycles, patients will receive better care. The event offers a great forum to connect with life science advocates and leaders.

To know more, please visit https://ibn.fm/3jfCh.

GolfLync, the pioneering golf social networking platform, is revolutionizing golf networking. GolfLync’s focus is on connecting like-minded players over their shared love for golf. New advanced filtering algorithms empower users to match with new players, find local friends, and discover new Virtual Golf Clubs (“VGC”) locally and while traveling. Now finding the perfect match is easier than ever!

Discovery Features: GolfLync’s discovery features allow members to set up filters for viewing content and connecting with members, whether on a local or national level. Easily find and engage with like-minded golfers.

Influencer Badges: GolfLync now offers influencer badges, earned by submitting government-issued IDs and undergoing validation, ensuring authenticity and trust.

Enhanced Reporting: Advanced screening tools allow users to filter, block, and report any spam, preserving the platform’s authenticity.

Verification Application: An in-app verification application enables users to apply for verified status, enhancing trust and recognition within the golfing community.

About GolfLync
GolfLync is the ultimate social media platform for golfers, connecting like-minded enthusiasts, fostering vibrant golfing communities, and redefining the golfing experience. With a user-friendly interface and advanced features, GolfLync brings golfers together and provides a space for golfers to connect, share, and celebrate their shared passion.

For more information about GolfLync and the groundbreaking initiatives that are transforming the golfing landscape, visit GolfLync and be part of a revolution in golfing camaraderie.

Available for free from both the Apple Store and Google Play stores. Create your account today and join in on the fun!

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study
• The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide
• Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group
• The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7% for the control group

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing human pilot study that seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide. The study, which focused on Rybelsus(R), a commercially available semaglutide drug, involved seven healthy subjects, four of whom received the DehydraTECH GLP-1, with the other three receiving the control (https://ibn.fm/2BPlK).

Of note was DehydraTECH GLP-1’s 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group. These results were achieved in the initial 100 minutes of taking the drugs, and at all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the control group. More so, even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline. In contrast, that of the control group was only reduced by 0.67%. This evidenced a nearly ten-fold improvement with DehydraTECH GLP-1.

When the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark, glucose levels spiked by 22.7% for the control group, while those in the DehydraTECH GLP-1 group only saw a 5.3% rise. Although this cannot be attributed to DehydraTECH GLP-1’s overall efficacy in achieving sustained blood glucose reduction, it is a plausible explanation for the difference and a pointer to the overall potential of the technology.

While there are still some additional steps to be taken, these positive results are welcome and point to the technology’s potential, specifically in diabetes treatment. In the DIAB-A22-1 animal study, Lexaria demonstrated at least three positive outcomes, which included weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The study also demonstrated an improvement in locomotor activity compared to untreated obese control rats, with no severe health concerns during dosing (https://ibn.fm/Bei48).

With the results from Lexaria’s DehydraTECH GLP-1, the company is on track to replicate the positive results from its diabetes study. More importantly, it is on track to carve out a decent market share in an industry projected to bring between $150 billion and $200 billion a year (https://ibn.fm/X03Wa). By doing so, it will also ensure that GLP-1 drugs are more effective with reduced side effects while also being accessible to individuals living with diabetes. It also hopes it will improve the quality of life of people living with the condition by offering a less intrusive and less painful treatment alternative than what is currently in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million
• The company intends to use the proceeds to pay an outstanding promissory note, advance development programs, and general corporate purposes
• PaxMedica received constructive feedback from its type-B meeting with the FDA, which will aid in completing the remaining paperwork necessary to file a New Drug Application
• The company is currently working on commercial lots of PAX-101, which are expected during the first half of 2024, for the New Drug Application, which is expected to be filed during the second half of 2024

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently reported the closing of its public offering. PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering (https://ibn.fm/XEIiL).

The previously announced public offering is an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock at a public offering price of $1.30 per share and accompanying warrant. The warrants have an exercise price of $1.30 per share and are exercisable immediately upon issuance – with an expiration of five years from the initial exercise date.

The company intends to use the net proceeds from this offering to repay an outstanding $0.2 million convertible promissory note held by Lind Global Fund II LP to advance PaxMedica’s development programs and for general corporate purposes.

Part of PaxMedica’s pipeline includes using suramin sodium in Stage One Human African Sleeping Sickness, which will help further the company’s efforts to develop therapies for ASD and other neurological symptoms. PaxMedica recently completed a type-B meeting with the FDA regarding the positive data results from its PAX-HAT-301 study.

The PAX-HAT-301 study is a retrospective, non-randomized, externally controlled, interventional efficacy and safety study comparing medical records data from a cohort of patients with Stage 1 Trypanosoma Brucei Rhodesiense (African Sleeping Sickness). These patients were treated from about 2000 to 2020 at a medical site in Uganda and two medical sites in Malawi. Medical records data from a cohort of patients from 1900 to 1910 from the TBR HAT epidemic in Uganda were also evaluated. The study aimed to determine if the treatments with suramin sodium from 2000 to 2020 were more effective at treating the disease than the outcomes observed in the epidemic over 100 years ago.

PaxMedica received constructive feedback, which will aid in completing the remaining paperwork necessary to file a New Drug Application (“NDA”), expected in the second half of 2024. Most of the work to achieve this milestone will focus on completing the production of commercial lots of PAX-101 under CMC regulatory guidelines, which are underway now and expected to conclude in the first half of 2024.

“This is an important turning point for our young company, and we are very pleased with the guidance that the FDA has provided us in this meeting,” said Howard Weisman, CEO and Chairman of PaxMedica (https://ibn.fm/CjaxD). “We look forward to urgently completing the necessary steps in the coming months to clear the path to submit our first NDA for PAX-101.”

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• D-Wave recently shared important research results demonstrating successful quantum error mitigation (“QEM”) in its Advantage2(TM) annealing quantum computing experimental prototype
• The company’s latest research focuses on zero-noise extrapolation, one of the most practical QEM techniques, maintaining the quantum state and reducing errors
• D-Wave has also made significant progress with high-coherence fluxonium qubits, setting new standards in quantum properties

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently shared important research results that demonstrate successful quantum error mitigation (“QEM”) in its Advantage2(TM) annealing quantum computing experimental prototype. This progress in reducing errors in quantum computers is expected to drive performance advancements in the company’s future quantum computing systems and processors.

Quantum computing is incredibly powerful but can be sensitive to noise and imperfections in the hardware – known as “errors.” Fixing these errors is a major challenge, and while there is a solution called quantum error correction, it’s currently too complex and resource-intensive to be practical. Instead, D-Wave has applied QEM as a near-term solution to estimate error-free expectation values in the presence of small noise.

D-Wave’s latest research focuses on zero-noise extrapolation (“ZNE”), one of the most practical QEM techniques. These techniques, used in the company’s Advantage2 annealing quantum computing experimental prototype, showed reduced errors in quantum simulation and produced results consistent with the quantum system maintaining its quantum state (known as “coherence”) for a much longer period of time compared to when no mitigation techniques are applied. This means better and more reliable results.

This breakthrough could translate to higher performance for D-Wave’s future quantum computers, like the upcoming Advantage2 system. Applying these research findings, D-Wave’s quantum systems and processors are expected to be able to tackle highly computationally complex problems in scientific-related and machine learning applications.

Mohammad Amin, a key researcher at D-Wave, underlined that errors are the biggest challenge in quantum computing. “With this research, we’ve demonstrated the successful mitigation of such errors in quantum annealing, producing measurement results as if the qubits were nearly one order of magnitude more coherent,” Amin said (https://ibn.fm/BYALl). “This opens up new possibilities, like simulating exotic materials and moving closer to achieving quantum supremacy on D-Wave processors.”

This isn’t the first time D-Wave has pushed the boundaries of quantum computing. Most recently, in September 2023, the company announced significant progress with high-coherence fluxonium qubits, which demonstrated quantum properties that are comparable to the best seen to date in scientific literature.

These fluxonium qubits are a key part of the next-generation quantum computers. D-Wave is especially interested in using them, as they’ve displayed some advantages over other types of qubits. The tests showed that these fluxonium qubits can stay stable for over 100 microseconds, and the measured effective temperature of its fluxonium, 18 millikelvin, is among the best that has been reported in the scientific literature to date for superconducting qubits.

“This shows that fluxonium is a viable candidate qubit for D-Wave’s gate model quantum computing architectures,” said Mark Johnson, SVP of quantum technologies at D-Wave (https://ibn.fm/0OpRu). “Moreover, in doing this work we have learned that fluxonium can address some of the known shortcomings of competing superconducting gate model qubits. We believe this will have a significant impact on D-Wave’s hardware development, and it also reinforces our technical leadership.”

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential impact and results of D-Wave’s progress in QEM; the new possibilities that may result from successful QEM including simulating exotic materials and moving closer to quantum supremacy on D-Wave processors; the potential impact of D-Wave’s work with fluxonium qubits on D-Wave’s hardware development and technical leadership. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the possibility for research results to differ in the future from what has been recorded to date; general economic conditions and other risks; D-Wave’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of D-Wave’s products; the effects of competition on the company’s business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of its securities; the risk that D-Wave’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

• Security tokens are becoming increasingly popular as minimized risk entry points for digital infrastructure markets, with smart algorithms beginning to effectively deal with redemption dispute resolution concerns
• Utah-based Diamond Lake Minerals recently shifted its focus from mining holdings to digital assets and security tokens offerings, and has seen its market interest rise in the process
• DLMI aims to build an industry-agnostic, vertically integrated holding company that helps its subsidiaries develop self-sufficiency while offering an inroad to experienced investors wary of digital asset involvement — functioning as a “generational wealth” bridge
• Some market insiders see tokenization as the launch of a new Golden Age in blockchain and traditional finance

As market traders increasingly adopt security tokens into their investment portfolios, a new period of market evolution is unfolding and multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) is developing a reputation for helping customers participate in new tech-based opportunities without having to figure out the intricacies of buying crypto and other digital assets.

The company’s market capitalization has jumped from “around a million dollars” to over $138 million in just a few months, accompanied by a significant boost in stock price, since it announced a shift into the digital asset and security token space.

“I believe DLMI is the hybrid missing piece to get generational wealth, or the wealth on the sidelines,” CEO Brian J. Esposito said during a November Bell2Bell podcast interview (https://ibn.fm/TGCaG). “(Experienced investors’) kids are involved with (digital assets). They hear about it at work. … Maybe they don’t trust it, maybe they don’t understand it, or they’re insecure about it, they don’t know how to download a digital wallet. So what we’re building is the ability to be involved in that space, through a regulated environment.”

DLMI’s market strategy involves building a vertically integrated ecosystem of numerous industry-agnostic holdings and imbuing each with a U.S. Securities and Exchange Commission (“SEC”)-registered security token offering (“STO”) designed to appeal to traditional investors who are otherwise unfamiliar with digital assets.

DLMI is not just another security token or digital asset company. It is building traditional businesses across multiple industries, and those business subsidiaries owned by DLMI will have security token offerings and components. The company will be properly including subsidiaries in their business models and in a regulated environment with their regulated SEC security token exchange partner INX (see INX link below).

Tokenization involves the use of digital assets that can be traded via protocols, and STOs attempt to provide confidence in the ability to redeem tokenized assets with minimal third-party involvement and maximum transparency.

The strength of DLMI’s approach to delivering tokenized rights to assets that have real value such as share ownership in real estate, investment funds and artwork is its adherence to U.S. Securities and Exchange Commission (“SEC”) regulations.

Web3 technologies such as decentralized finance (“DeFi”) and non-fungible tokens (“NFTs”) have installed the technological infrastructure to enable a new financial system, and tokenization of real world assets (“RWAs”) is expected to herald a new Golden Age in blockchain as well as traditional finance by unlocking the transfer of trillions of dollars of value into crypto, according to crypto media outlet CoinDesk (https://ibn.fm/2jOjh).

“The next generation for markets, the next generation for securities, will be tokenization of securities,” world-leading asset manager BlackRock’s CEO Larry Fink told the outlet.

DLMI is starting, acquiring and building a wide variety of subsidiaries that will “share resources, support one another, and ensure that if there’s a downside in one industry or segment, that we have a diversified model to help keep everything afloat and everything growing,” Esposito said.  “I love working in the regulated environment because it’s a place that helps ensure protecting people.”

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• CEO and President Samuel David discussed the success of Prospera’s drilling program in recent interview, revealed positive results and cost reductions
• Prospera management estimates as little as 8% of over half a billion barrels across assets have been recovered using traditional vertical well technology
• Phase 2 of drilling program focused on transition from vertical to horizontal well drilling, allowing the company to tap into the significant remaining reserves
• Recent Q3 2023 financial highlights include Q/Q rise in operating income from $783,084 to $1,101,827 and positive net income of $71,011 compared to net loss of $779,438 in Q2 2023

Samuel David, President and CEO of Prospera Energy (TSX.V: PEI) (OTC:s GXRFF) (FRA: OF6B), recently discussed the company’s successful drilling program in an interview on the Financial Survival Network (https://ibn.fm/44mbK).

“We have drilled five horizontals and infield drilling based on geological well delineation, well control, and seismic delineation,” said Mr. David during the interview. “Therefore, the chance of success of geological, of finding the reservoir, is high. The only risk is mechanical because this is infill low-risk drilling. We tweaked it by drilling a couple of pilot wells prior to embarking on this development program.”

“These wells encountered pay structure and oil as we expected, and we came in under budget by about 15%. I think we can even tweak that a little bit more as we extend the drilling.”

Prospera recently transformed into a sustainable energy producer that focuses on efficient hydrocarbon development, recovery, and production practices. Assets include 42,000+ acres across Cuthbert, Luseland and Heart Hills in Saskatchewan, and Red Earth and Pouce Coupe in Alberta.

Company management estimates that roughly 8% of over half a billion available barrels have been recovered using traditional vertical well technology. Phase 2 encompasses a drilling program focused on transitioning from vertical to horizontal wells, allowing the company to increase production rates and tap into additional reserves. Following several production setbacks caused by adverse weather conditions, the company has achieved peak rates of 770+ barrels of oil equivalent per day (boe/d), with an additional 350 boe/d positioned for optimization.

The company recently revealed promising results from its restructuring efforts in a financial update (https://ibn.fm/MT0Er). Highlights include a Q/Q rise in operating income from $783,084 in 2022 to $1,101,827 in 2023. The company also reported a net income of $71,011 in Q3 2023 – a substantial turnaround from a net loss of $779,438 in Q2 2023. Further, the company announced it raised C$580,000 through the first closing of a private placement debt financing with an equity bonus. Funds from the closing are targeted for drilling, completion, tie-in, well abandonment and reclamation costs, and ongoing ESG initiatives.

“Next summer we got a huge reclamation program to turn all of this back to farming lands, reducing the environmental footprint,” continued Mr. David. “That will also reduce a tremendous amount to the bottom line and opex (operating expenses).”

Samuel David leads Prospera Energy with over 32 years of development and management experience in the oil and gas sectors. Joining him is a diverse team of industry veterans leveraging business development and finance expertise to strategically optimize the company for sustainable growth and profitability.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF